Oleylphosphocholine (OlPC) arrests Cryptosporidium parvum growth in vitro and prevents lethal infection in interferon gamma receptor knock-out mice

Frontiers in Microbiology

Volumn 6, Issue SEP, 2015, Pages

  Sonzogni Desautels, Karine ^a,b   Renteria, Axel E ^a,c   Camargo, Fabio V ^a   Di Lenardo, Thomas Z ^c   Mikhail, Alexandre ^a   Arrowood, Michael J ^d   Fortin, Anny ^c,e   Ndao, Momar ^a,b,c  

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^e Dafra Pharma nv   (Belgium)

Author keywords

Cryptosporidiosis; Cryptosporidium parvum; Interferon gamma receptor knockout mice; Miltefosine; Oleylphosphocholine; OlPC; Oocysts; Parasite burden

Indexed keywords

ANTIPARASITIC AGENT; GAMMA INTERFERON RECEPTOR; MILTEFOSINE; OLEYLPHOSPHOCHOLINE; PAROMOMYCIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRYPTOSPORIDIOSIS; CRYPTOSPORIDIUM PARVUM; DRUG CYTOTOXICITY; DRUG DOSE COMPARISON; EC50; FECES ANALYSIS; FEMALE; FLOW CYTOMETRY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; ILEUM; KNOCKOUT MOUSE; MALE; MICROBIAL GROWTH; MICROSCOPY; MORTALITY; MOUSE; NONHUMAN; OOCYST; PARASITE CLEARANCE; PARASITE LOAD; POLYMERASE CHAIN REACTION; SURVIVAL RATE; WEIGHT REDUCTION; XTT ASSAY;

EID: 84946735781     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2015.00973     Document Type: Article

References (49)

1. Anthony, M. L., Zhao, M., and Brindle, K. M. (1999). Inhibition of phosphatidylcholine biosynthesis following induction of apoptosis in HL-60 cells. J. Biol. Chem. 274, 19686-19692. doi: 10.1074/jbc.274.28.19686
2. Armson, A., Meloni, B. P., Reynoldson, J. A., and Thompson, R. C. (1999). Assessment of drugs against Cryptosporidium parvum using a simple in vitro screening method. FEMS Microbiol. Lett. 178, 227-233. doi: 10.1111/j.1574-6968.1999.tb08681.x
3. Berkman, D. S., Lescano, A. G., Gilman, R. H., Lopez, S. L., and Black, M. M. (2002). Effects of stunting, diarrhoeal disease, and parasitic infection during infancy on cognition in late childhood: a follow-up study. Lancet 359, 564-571. doi: 10.1016/S0140-6736(02)07744-9
4. Blagburn, B. L., Sundermann, C. A., Lindsay, D. S., Hall, J. E., and Tidwell, R. R. (1991). Inhibition of Cryptosporidium parvum in neonatal Hsd:(ICR)BR Swiss miceby polyether ionophores and aromatic amidines. Antimicrob. Agents Chemother. 35, 1520-1523. doi: 10.1128/AAC.35.7.1520
5. Bouzid, M., Hunter, P., Chalmers, R., and Tyler, K. (2013). Cryptosporidium pathogenicity and virulence. Clin. Microbiol. Rev. 26, 115-134. doi: 10.1128/CMR.00076-12
6. Cabada, M., and White, A. C. (2010). Treatment of cryptosporidiosis: do we know what we think we know? Curr. Opin. Infect. Dis. 23, 494-499. doi: 10.1097/QCO.0b013e32833de052
7. Cacciò, S. M., and Putignani, L. (2014). "Epidemiology of human cryptosporidiosis," in Cryptosporidium: Parasite and Disease, eds S. M. Caccio and G. Widmer (Vienna: Springer), 43-79.
8. Cacciò, S. M., Thompson, R. C., Mclauchlin, J., and Smith, H. V. (2005). Unravelling Cryptosporidium and Giardia epidemiology. Trends Parasitol. 21, 430-437. doi: 10.1016/j.pt.2005.06.013
9. CDC. (2013). Investigational drug available directly from CDC for the treatment of infections with free-living amebae. MMWR 62:666.
10. Chalmers, R. M., and Davies, A. P. (2010). Minireview: clinical cryptosporidiosis. Exp. Parasitol. 124, 138-146. doi: 10.1016/j.exppara.2009.02.003
11. Chen, X.-M., Keithly, J. S., Paya, C. V., and Larusso, N. F. (2002). Cryptosporidiosis. N. Engl. J. Med. 346, 1723-1731. doi: 10.1056/NEJMra013170
12. Collinet-Adler, H. D., and Ward, H. D. (2010). Cryptosporidiosis: environmental, therapeutic, and preventive challenges. Euro. J. Clin. Microbiol. Infect. Dis. 29, 927-935. doi: 10.1007/s10096-010-0960-9
13. Costa, L., Noronha, F., Roche, J., Sevilleja, J., Warren, C., Oriã, R., et al. (2012). Novel in vitro and in vivo models and potential new therapeutics to break the vicious cycle of Cryptosporidium infection and malnutrition. J. Infect. Dis. 205, 1464-1471. doi: 10.1093/infdis/jis216
14. Dorlo, T. P. C., Balasegaram, M., Beijnen, J., and De Vries, P. (2012). Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis. J. Antimicrob. Chemother. 67, 2576-2597. doi: 10.1093/jac/dks275
15. Downey, A. S., Chong, C. R., Graczyk, T. K., and Sullivan, D. J. (2008). Efficacy of pyrvinium pamoate against Cryptosporidium parvum infection in vitro and in a neonatal mouse model. Antimicrob. Agents Chemother. 52, 3106-3112. doi: 10.1128/AAC.00207-08
16. Fayer, R., Morgan, U., and Upton, S. J. (2000). Epidemiology of Cryptosporidium: transmission, detection and identification. Int. J. Parasitol. 30, 1305-1322. doi: 10.1016/S0020-7519(00)00135-1
17. Fayer, R., and Xiao, L. (2008). Cryptosporidium and Cryptosporidiosis. Boca Raton: CRC Press.
18. FDA. (2014). Fda Approves Impavido to Treat Tropical Disease Leishmaniasis. Available at: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm389671.htm [accessed 17 April 2014].
19. Feldmann, H., Czub, M., Jones, S., Dick, D., Garbutt, M., Grolla, A., et al. (2002). Emerging and re-emerging infectious diseases. Med. Microbiol. Immunol. 191, 63-74. doi: 10.1007/s00430-002-0122-5
20. Fortin, A., Caridha, D. P., Leed, S., Ngundam, F., Sena, J., Bosschaerts, T., et al. (2014). Direct comparison of the efficacy and safety of oral treatments with oleylphosphocholine (OlPC) and miltefosine in a mouse model of L. major cutaneous leishmaniasis. PLoS Negl. Trop. Dis. 8:e3144. doi: 10.1371/journal.pntd.0003144
21. Fortin, A., Hendrickx, S., Yardley, V., Cos, P., Jansen, H., and Maes, L. (2012). Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. J. Antimicrob. Chemother. 67, 2707-2712. doi: 10.1093/jac/dks273
22. Guerrant, R. L. (1997). Cryptosporidiosis: an emerging, highly infectious threat. Emerg. Infect. Dis. 3, 51-57. doi: 10.3201/eid0301.970106
23. Healey, M. C., Yang, S., Rasmussen, K. R., Jackson, M. K., and Du, C. (1995). Therapeutic efficacy of paromomycin in immunosuppressed adult mice infected with Cryptosporidium parvum. J. Parasitol. 81, 114-116. doi: 10.2307/3284020
24. Hernandez, L., Galvez, R., Montoya, A., Checa, R., Bello, A., Bosschaerts, T., et al. (2014). First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum. Parasitol. Res. 113, 157-164. doi: 10.1007/s00436-013-3638-2
25. Hewitt, R. G., Yiannoutsos, C. T., Higgs, E. S., Carey, J. T., Geiseler, P. J., Soave, R., et al. (2000). Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin. Infect. Dis. 31, 1084-1092. doi: 10.1086/318155
26. King, B., Keegan, A., Monis, P., and Saint, C. (2005). Environmental temperature controls Cryptosporidium oocyst metabolic rate and associated retention of infectivity. Appl. Environ. Microbiol. 71, 3848-3857. doi: 10.1128/AEM.71.7.3848-3857.2005
27. Kotloff, K. L., Nataro, J. P., Blackwelder, W. C., Nasrin, D., Farag, T. H., Panchalingam, S., et al. (2013). Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-control study. Lancet 382, 209-222. doi: 10.1016/S0140-6736(13)60844-2
28. Mead, J. R., and Arrowood, M. J. (2014). "Treatment of cryptosporidiosis," in Cryptosporidium: Parasite and Disease, eds S. M. Caccio and G. Widmer (Vienna: Springer), 455-486.
29. Mead, J. R., and You, X. (1998). Susceptibility differences to Cryptosporidium parvum infection in two strains of gamma interferon knockout mice. J. Parasitol. 84, 1045-1048. doi: 10.2307/3284643
30. Mead, J. R., You, X., Pharr, J. E., Belenkaya, Y., Arrowood, M. J., Fallon, M. T., et al. (1995). Evaluation of maduramicin and alborixin in a SCID mouse model of chronic cryptosporidiosis. Antimicrob. Agents Chemother. 39, 854-858. doi: 10.1128/AAC.39.4.854
31. Meloni, B. P. (1996). Simplified methods for obtaining purified oocysts from mice and for growing Cryptosporidium parvum in vitro. J. Parasitol. 82, 757-762. doi: 10.2307/3283888
32. Ndao, M., Nath Chowdhury, M., Sajid, M., Marcus, V., Mashiyama, S., Sakanari, J., et al. (2013). A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection. Antimicrob. Agents Chemother. 57, 6063-6073. doi: 10.1128/AAC.00734-13
33. Putignani, L., and Menichella, D. (2010). Global distribution, public health and clinical impact of the protozoan pathogen Cryptosporidium. Interdiscip. Perspect. Infect. Dis. 2010, 753512.
34. Richard, S., Black, R., Gilman, R., Guerrant, R., Kang, G., Lanata, C., et al. (2014). Catch-up growth occurs after diarrhea in early childhood. J. Nutr. 144, 965-971. doi: 10.3945/jn.113.187161
35. Robertson, L. J., Campbell, A. T., and Smith, H. V. (1992). Survival of Cryptosporidium parvum oocysts under various environmental pressures. Appl. Environ. Microbiol. 58, 3494-3500.
36. Roehm, N. W., Rodgers, G. H., Hatfield, S. M., and Glasebrook, A. L. (1991). An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 142, 257-265. doi: 10.1016/0022-1759(91)90114-U
37. Rossignol, J.-F. (2010). Cryptosporidium and Giardia: treatment options and prospects for new drugs. Exp. Parasitol. 124, 45-53. doi: 10.1016/j.exppara.2009.07.005
38. Rotz, L. D., Khan, A. S., Lillibridge, S. R., Ostroff, S. M., and Hughes, J. M. (2002). Public health assessment of potential biological terrorism agents. Emerg. Infect. Dis. 8, 225-230. doi: 10.3201/eid0802.010164
39. Ryan, U., and Xiao, L. (2014). "Taxonomy and molecular taxonomy," in Cryptosporidium: Parasite and Disease, eds S. M. Caccio and G. Widmer (Vienna: Springer), 3-41.
40. Shahiduzzaman, M., Dyachenko, V., Obwaller, A., Unglaube, S., and Daugschies, A. (2009). Combination of cell culture and quantitative PCR for screening of drugs against Cryptosporidium parvum. Vet. Parasitol. 162, 271-277. doi: 10.1016/j.vetpar.2009.03.009
41. Shikani, H., and Weiss, L. M. (2014). "Human cryptosporidiosis: a clinical perspective," in Cryptosporidium: Parasite and Disease, eds S. M. Caccio and G. Widmer (Vienna: Springer), 383-421.
42. Thapar, N., and Sanderson, I. R. (2004). Diarrhoea in children: an interface between developing and developed countries. Lancet 363, 641-653. doi: 10.1016/S0140-6736(04)15599-2
43. Tzipori, S., Rand, W., and Theodos, C. (1995). Evaluation of a two-phase scid mouse model preconditioned with anti-interferon-gamma monoclonal antibody for drug testing against Cryptosporidium parvum. J. Infect. Dis. 172, 1160-1164. doi: 10.1093/infdis/172.4.1160
44. van Blitterswijk, W. J., and Verheij, M. (2008). Anticancer alkylphospholipids: mechanisms of action, cellular sensitivity and resistance, and clinical prospects. Curr. Pharm. Des. 14, 2061-2074. doi: 10.2174/138161208785294636
45. von Oettingen, J., Nath-Chowdhury, M., Ward, B. J., Rodloff, A. C., Arrowood, M. J., and Ndao, M. (2008). High-yield amplification of Cryptosporidium parvum in interferon γ receptor knockout mice. Parasitology 135, 1151-1156. doi: 10.1017/S0031182008004757
46. Widmer, G., Corey, E. A., Stein, B., Griffiths, J. K., and Tzipori, S. (2000). Host cell apoptosis impairs Cryptosporidium parvum development in vitro. J. Parasitol. 86, 922-928.
47. Yang, S., Benson, S. K., Du, C., and Healey, M. C. (2000). Infection of immunosuppressed C57BL/6N adult mice with a single oocyst of Cryptosporidium parvum. J. Parasitol. 86, 884-887. doi: 10.2307/3284990
48. Yang, S., and Healey, M. C. (1993). The immunosuppressive effects of dexamethasone administered in drinking water to C57BL/6N mice infected with Cryptosporidium parvum. J. Parasitol. 79, 626-630. doi: 10.2307/3283395
49. You, X., and Mead, J. R. (1998). Characterization of experimental Cryptosporidium parvum infection in IFN-gamma knockout mice. Parasitology 117(Pt 6), 525-531. doi: 10.1017/S0031182098003424